Admedus Limited
(ASX:AHZ) General Manager - Americas Tom Riester presents at ASX Spotlight Series in New York.
Mr Riester provides a business overview of Amedus’ operations and details the company’s offerings.
The diversified healthcare group’s presentation also covers regenerative medicine, immunotherapies, company milestones and news flow.
Discussing the company’s highlights Mr Riester says, “Nearterm company milestones and news flow we look at in the rear-view mirror over the last twelve months. Very exciting.
We came into the calendar year with a number of questions... Will we get clearance in the US, will surgeons buy based on the data that we had? And all those questions got answered very favourably and positively.
Approval for CardioCel in Europe, we got our clearance here in the US, we got clearance now in Canada, we’ve got special access in Singapore, in addition early access for CardioCel in other markets and most importantly we are driving revenue from the product.”
